Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

被引:147
作者
Borah, A. [1 ]
Raveendran, S. [1 ]
Rochani, A. [1 ]
Maekawa, T. [1 ]
Kumar, D. S. [1 ]
机构
[1] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bio Nano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan
来源
ONCOGENESIS | 2015年 / 4卷
关键词
HEDGEHOG SIGNALING PATHWAY; BETA-CATENIN EXPRESSION; ACUTE MYELOID-LEUKEMIA; EPITHELIAL-MESENCHYMAL TRANSITION; SMALL-MOLECULE INHIBITOR; POLYCOMB-GROUP ONCOGENES; PANCREATIC-CANCER; BREAST-CANCER; PROSTATE-CANCER; TUMOR-GROWTH;
D O I
10.1038/oncsis.2015.35
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy.
引用
收藏
页码:e177 / e177
页数:11
相关论文
共 153 条
  • [91] Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas
    Nagayama, S
    Fukukawa, C
    Katagiri, T
    Okamoto, T
    Aoyama, T
    Oyaizu, N
    Imamura, M
    Toguchida, J
    Nakamura, Y
    [J]. ONCOGENE, 2005, 24 (41) : 6201 - 6212
  • [92] Tumour-initiating cells vs. cancer 'stem' cells and CD133: What's in the name?
    Neuzil, Jiri
    Stantic, Marina
    Zobalova, Renata
    Chladova, Jaromira
    Wang, Xiufang
    Prochazka, Lubomir
    Dong, Lanfeng
    Andera, Ladislav
    Ralph, Stephen J.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 355 (04) : 855 - 859
  • [93] Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells
    Ni, Miaozhong
    Xiong, Min
    Zhang, Xinchao
    Cai, Guoping
    Chen, Huaiwen
    Zeng, Qingmin
    Yu, Zuochong
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 : 2537 - 2554
  • [94] Wnt Signaling and Stem Cell Control
    Nusse, R.
    Fuerer, C.
    Ching, W.
    Harnish, K.
    Logan, C.
    Zeng, A.
    Ten Berge, D.
    Kalani, Y.
    [J]. CONTROL AND REGULATION OF STEM CELLS, 2008, 73 : 59 - 66
  • [95] Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
    Olive, Kenneth P.
    Jacobetz, Michael A.
    Davidson, Christian J.
    Gopinathan, Aarthi
    McIntyre, Dominick
    Honess, Davina
    Madhu, Basetti
    Goldgraben, Mae A.
    Caldwell, Meredith E.
    Allard, David
    Frese, Kristopher K.
    DeNicola, Gina
    Feig, Christine
    Combs, Chelsea
    Winter, Stephen P.
    Ireland-Zecchini, Heather
    Reichelt, Stefanie
    Howat, William J.
    Chang, Alex
    Dhara, Mousumi
    Wang, Lifu
    Rueckert, Felix
    Gruetzmann, Robert
    Pilarsky, Christian
    Izeradjene, Kamel
    Hingorani, Sunil R.
    Huang, Pearl
    Davies, Susan E.
    Plunkett, William
    Egorin, Merrill
    Hruban, Ralph H.
    Whitebread, Nigel
    McGovern, Karen
    Adams, Julian
    Iacobuzio-Donahue, Christine
    Griffiths, John
    Tuveson, David A.
    [J]. SCIENCE, 2009, 324 (5933) : 1457 - 1461
  • [96] Palacios J, 1998, CANCER RES, V58, P1344
  • [97] Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
    Pandya, K.
    Meeke, K.
    Clementz, A. G.
    Rogowski, A.
    Roberts, J.
    Miele, L.
    Albain, K. S.
    Osipo, C.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (06) : 796 - 806
  • [98] Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
    Peacock, Craig D.
    Wang, Qiuju
    Gesell, Gregory S.
    Corcoran-Schwartz, Ian M.
    Jones, Evan
    Kim, Jynho
    Devereux, Wendy L.
    Rhodes, Jonathan T.
    Huff, Carol A.
    Beachy, Philip A.
    Watkins, D. Neil
    Matsui, William
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (10) : 4048 - 4053
  • [99] Canonical Wnt signals are essential for homeostasis of the intestinal epithelium
    Pinto, D
    Gregorieff, A
    Begthel, H
    Clevers, H
    [J]. GENES & DEVELOPMENT, 2003, 17 (14) : 1709 - 1713
  • [100] Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors
    Raaphorst, FM
    [J]. HUMAN MOLECULAR GENETICS, 2005, 14 : R93 - R100